SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ISENTRESS

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2007. No further regulatory approval milestones are pending.
Why 3/10
ISENTRESS is an already-approved, marketed drug with no pending regulatory decision or pivotal readout scheduled in the next ~12 months. As a mature product facing generic erosion, it has no hard binary catalyst ahead.
Actionable Insight NEUTRAL

ISENTRESS is a mature, declining asset for Merck with no upcoming binary catalysts. The key dynamic to watch is the pace of generic erosion: Hetero Labs received final FDA approval for generic raltegravir 400mg in December 2024, and Lupin has tentative approval for the 600mg HD version. Continued sales declines are baked into expectations, but any faster-than-expected erosion or a major label expansion for a newer integrase inhibitor from a competitor could modestly pressure Merck's HIV franchise revenue. For Merck investors, ISENTRESS is a negligible factor relative to Keytruda, Gardasil, and Winrevair.

Price Chart

Loading chart...

Executive Summary

ISENTRESS (raltegravir) is Merck & Co.'s first-in-class HIV-1 integrase inhibitor, first approved by the FDA in October 2007. It is a mature, approved product with no pending regulatory catalysts. The drug faces growing headwinds: generic competition entered the market in December 2024 (Hetero Labs received final FDA approval for generic raltegravir 400mg), and newer once-daily integrase inhibitors like dolutegravir and bictegravir have eroded its market position. Sales have been declining (roughly $394M in 2024, down from $483M in 2023). Merck has extended the franchise with ISENTRESS HD (once-daily 1200mg), a pediatric oral suspension, and a neonatal indication, but these are niche additions. For Merck, a $346B market cap company with $65B in annual revenue, ISENTRESS is a negligible revenue contributor (less than 1% of sales) and not a stock-moving catalyst in either direction.

How It Works

ISENTRESS is an antiretroviral drug that treats HIV-1 infection by blocking an enzyme called integrase, which the HIV virus needs to insert its genetic material into the DNA of human immune cells. By stopping this integration step, the drug prevents the virus from replicating and reduces the viral load in the body. It is always used in combination with other antiretroviral agents, never as a standalone treatment.

Trial Status

ISENTRESS is a fully approved, commercially marketed drug. The most recent label expansion was FDA approval for use in neonates (newborns from birth to 4 weeks of age weighing at least 2 kg), supported by the IMPAACT P1110 study. A pediatric oral suspension formulation was also approved. No active pivotal clinical trials are ongoing for new indications.

The Two-Sided Case

▲ Bull Case4
ISENTRESS remains the only integrase inhibitor approved in the U.S. for treating HIV-1 in neonates (newborns from birth to 4 weeks of age weighing at least 2 kg), a niche but important label advantage that generics cannot easily replicate.
Merck has expanded the franchise with ISENTRESS HD (1200mg once-daily) and a pediatric oral suspension formulation, extending the product's lifecycle and addressing specific patient populations.
The drug has a well-established safety and efficacy profile with over 18 years of real-world use, which supports continued prescribing in appropriate patients, particularly in treatment-experienced populations and resource-limited settings.
As a small part of a diversified giant like Merck, ISENTRESS carries no company-level risk; its decline is already priced into the broader Merck thesis.
▼ Bear Case4
Generic competition is now in the market: Hetero Labs received final FDA approval for generic raltegravir 400mg on December 19, 2024, and Lupin has tentative approval for the 600mg HD version with 180-day exclusivity eligibility, which will erode branded ISENTRESS pricing and volume.
ISENTRESS is a first-generation integrase inhibitor with twice-daily dosing (400mg) that is losing ground to newer once-daily integrase inhibitors like dolutegravir (ViiV/GSK) and bictegravir (Gilead), which offer better resistance profiles and convenience.
Sales are declining: PharmaCompass data shows ISENTRESS revenue fell from $483M in 2023 to $394M in 2024, a roughly 18% decline, and the trend is likely accelerating with generic entry.
ISENTRESS is a very small part of Merck's overall business (less than 1% of Merck's $65B in 2025 revenue), so even a complete loss of the franchise would have negligible impact on the stock.

Upcoming Catalysts

  • No upcoming binary catalysts for ISENTRESS specifically. The drug is mature and facing generic erosion. Merck's overall Q3 2026 earnings were reported on October 29, 2026 (today), but ISENTRESS is too small to move the stock.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 14

Hover a chip for the title
1 merck.com2 sec.gov3 merck.com4 accessdata.fda.gov5 lupin.com6 merck.com7 merck.com8 drugs.com9 pharmacompass.com10 drugs.com11 drugpatentwatch.com12 en.wikipedia.org13 sec.gov14 cnbc.com